Professor Rui-Hua Xu has been engaged in clinical work and medical oncology research for more than 30 years. He has made many substantial contributions that have led to international acclaim in the field of gastrointestinal cancers, in regards to early diagnosis, screening, treatments, metastasis, and research in cancer drug resistance. He has published more than 160 peer-reviewed papers (including 22 papers with an IF score of >10) in top international journals such as Nature Materials and the Lancet Oncology as the corresponding author or first author. More importantly, the results of his studies continue to be internationally impactful and have been cited by 17 international guidelines. He has also led the development of 9 national medical treatment guidelines. Professor Xu is also the recipient of two National Science and Technology Progress Awards (2nd level) and six provincial and ministerial awards (1st level), including the Chinese Medical Science and Technology Award, among many more.

For information on Professor Xu's laboratory, click here and select: Metastasis Molecular Mechanism/Biomarkers for Individual Therapy.

M.D. School of Medicine, Jiangxi Medical College, China, 1983-1988 

Master Degree in Oncology, Sun Yat-Sen University of Medical Sciences, China, 1991-1994

Ph.D in Oncology, Sun Yat-Sen University of Medical, China, 1997-2000

Selected publications

1. Xu RH#*, Wei W#, Krawczyk M#, Wang W#, Luo H#, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey BA, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu JK, Hao X, Zhang K*. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nature Materials. 2017 Nov;16(11):1155-1161. (IF: 38.9)

2. Xu RH#*, Muro K#*, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS*, Kim TW*. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncology. 2018 May;19(5):660-671. (IF: 35.4)

3. Huiyan Luo#, Guoliang Xu#, Chaofeng Li#, Longjun He#, Linna Luo#, Zixian Wang#, Bingzhong Jing, Yishu Deng, Ying Jin, Yin Li, Bin Li, Wencheng Tan, Caisheng He, Sharvesh Raj Seeruttun, Qiubao Wu, Jun Huang, De-wang Huang, Bin Chen, Shao-bin Lin, Qin-ming Chen, Chu-ming Yuan, Hai-xin Chen, Heng-ying Pu, Feng Zhou, Yun He, Rui-hua Xu*. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncology. October 4, 2019 https://doi.org/10.1016/S1470-2045(19)30637-0. (IF: 35.4)

4. Feng Wang#, Qi Zhao#, Ying-NanWang, Jing Jin, Ming-Ming He, Ze-Xian Liu, Rui-Hua Xu*. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncology. 2019;5(10):1504-1506. (IF: 22.4)

5. Wang DS#, Liu ZX#, Lu YX#, Bao H, Wu X, Zeng ZL, Liu Z, Zhao Q, He CY, Lu JH, Wang ZQ, Qiu MZ, Wang F, Wang FH, Li YH, Wang XN, Xie D, Jia WH, Shao YW, Xu RH*. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut. 2018 Sep 29. pii: gutjnl-2018-316522. (IF: 17.9)

6. Huiyan Luo#, Qi Zhao#, Wei Wei#, Lianghong Zheng#, Shaohua Yi#, Gen Li, Wenqiu Wang, Hui Sheng, Hengying Pu, Haiyu Mo, Zhixiang Zuo, Zexian Liu, Chaofeng Li, Chuanbo Xie, Zhaolei Zeng, Weimin Li, Xiaoke Hao, Yuying Liu, Sumei Cao, Wanli Liu, Sarah Gibson, Kang Zhang, Guoliang Xu, Rui-hua Xu. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction and 1 screening of colorectal cancer. Science Translational Medicine 12, eaax7533 (2020). (IF 17.2)

7. Chen DL#, Wang ZQ#, Zeng ZL#, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH, Xu RH*. Identification of miR-214 as a negative regulator of colorectal cancer liver metastasis via regulation of FGFR1 expression. Hepatology，2014 Aug;60(2):598-609. (IF: 14.9)

8. Luo HY#, Li YH#, Wang W, Wang ZQ, Yuan X, Ma D, Wang FH, Zhang DS, Lin DR, Lin YC, Jia J, Hu XH, Peng JW, Xu RH*. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Ann Oncol. 2016 Jun;27(6):1074-81. (IF: 14.2)

9. F. Wang#, X. L. Wei#, F. H. Wang#, N. Xu, L. Shen, G. H. Dai, X. L. Yuan, Y. Chen, S. J. Yang, J. H. Shi, X. C. Hu, X. Y. Lin, Q. Y. Zhang, J. F. Feng, Y. Ba, Y. P. Liu, W. Li, Y. Q. Shu, Y. Jiang, Q. Li, J. W. Wang, H.Wu, H. Feng, S. Yao & R. H. Xu*. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemorefractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 0: 1–8, 2019 doi:10.1093/annonc/mdz197. (IF: 14.2)

10. Ju HQ#, Lu YX#, Chen DL#, Zuo ZX, Liu ZX, Wu QN, Mo HY, Wang ZX, Wang DS, Pu HY, Zeng ZL, Li B, Xie D, Huang P, Hung MC, Chiao PJ, Xu RH*. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. Journal of National Cancer Institute. 2018 Dec 8. doi: 10.1093/jnci/djy160. (IF: 10.2)

Updated May 2020

Dr Li Zhang is Professor of Medical Oncology, Director of Phase I Unit of Sun Yat-Sen University Cancer Centre (SYSUCC), Deputy Director of Lung Cancer Research Centre of SYSU. He is also the member of ASCO, CSCO, ESMO, IASLC, MASCC and Member of communication committee of IASLC. Professor Zhang has published more than 200 clinical papers in top-tier journals like: Lancet, Lancet Oncology, Lancet Respiratory Medicine, Journal of Clinical Oncology, JAMA Oncology, Nature Communications, Annals of Oncology, JTO, JNCI. He also presented abstracts to many major congresses like ASCO, WCLC, ESMO, MASCC meetings.  He is an editorial board member of Clinical Lung Cancer, Chinese Journal of Clinical Oncology, and Cancer Communications. At present, he is a senior consultant to the Centre of Drug Evaluation, Chinese Food and Drug Administration (CFDA) and had formerly drafted the CFDA Guidance for Industry: Clinical Trial for the Approval of Cancer Drugs and Biologics (second version, 2006).

Dr Zhang received his master of clinical oncology degree from SYSU and was board certified as a physician in medical oncology. He has completed training as a visiting fellow at the MD Anderson Cancer Centre, Houston; Fox Chase Cancer Centre, Philadelphia, USA and Institut Gustave Roussy, Paris, France.

Selected publications

1. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.  Li Zhang, Y Huang, S Hong, Y Yang, G Yu, J Jia, P Peng, X Wu, Q Lin, X Xi, J Peng, M Xu, D Chen, X Lu, R Wang, X Cao, X Chen, Z Lin, J Xiong, Q Lin, C Xie, Z Li, J Pan, J Li, S Wu, Y Lian, Q Yang, C Zhao The Lancet 2016

2. Efficacy and tolerability data from a randomised, placebo-controlled, parallel-group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804). Li Zhang, S Ma, X Song, B Han, Y Cheng, C Huang, S Yang, X Liu, Y Liu, S Lu, J Wang, S Zhang, C Zhou, X Zhang, N Hayashi, M Wang.  Lancet Oncology 2012

3. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. W Fang, Y Yang, Y Ma, S Hong, L Lin, X He, J Xiong, P Li, H Zhao, Y Huang, Y Zhang, L Chen, N Zhou, Y Zhao, X Hou, Q Yang, Li Zhang  Lancet Oncology 2018

4. Challenges in anticancer drug R&D in China.  S Zhao, C Lv, J Gong, W Fang, X Hu, Y Ba, X Chen, Z Yang, L Shen, Li Zhang Lancet Oncology 2019

5. ALESIA: a randomised phase 3 study of alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. C Zhou, S Kim, T Reungwetwattana, J Zhou, Y Zhang, J He, J Yang, Y Cheng, S Lee, L Bu, T Xu, L Yang, C Wang, T Liu, P N. Morcos, Y Lu, Li Zhang The Lancet Respiratory Medicine 2019

6. Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.     Y Yang, J Zhou, J Zhou, J Feng, W Zhuang, J Chen, J Zhao, W Zhong, Y Zhao, Y Zhang, Y Song, Y Hu, Z Yu, Y Gong, Y Chen, F Ye, S Zhang, L Cao, Y Fan, G Wu, Y Guo, C Zhou, K Ma, J Fang, W Feng, Y Liu, Z Zheng, G Li, N Wu, W Song, X Liu, S Zhao, L Ding, L Mao, G Selvaggi, X Yuan, Y Fu, T Wang, S Xiao, Li Zhang  The Lancet Respiratory Medicine 2020

7. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results.  Zhang L, Zhao C, Peng PJ, Lu LX, Huang PY, Han F, Wu SX.  Journal of Clinical Oncology 2005

8. Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non–Small Cell Lung Cancer. S Hong, F Gao, S Fu, Y Wang, W Fang, Y Huang, Li Zhang. JAMA Oncology 2018

9. The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma. Hong S, Liu D, Luo S, Fang W, Zhan J, Fu S, Zhang Y, Wu X, Zhou H, Chen X, Chen G, Zhang Z, Zheng Q, Li X, Chen J, Liu X, Lei M, Ye C, Wang J, Yang H, Xu X, Zhu S, Yang Y, Zhao Y, Zhou N, Zhao H, Huang Y, Zhang L, Wu K, Zhang Li. Nature Communications 2019

10. Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis.  Y Zhang, Y Yang, Z Zhang, W Fang, S Kang, Y Luo, J Sheng, J Zhan, S Hong, Y Huang, N Zhou, H Zhao, Li Zhang  Journal of The National Cancer Institute 2017

11. Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer. W Fang, Y Ma, J Yin, S Hong, H Zhou, A Wang, F Wang, H Bao, X Wu, Y Yang, Y Huang, H Zhao, Y Shao, Li Zhang Clinical Cancer Research 2019

Last updated: April 2020

The Preliminary Results of Advanced and Recurrent Malignant Lymphoma Treated by BEAC Regimen Supported with Autologous Hematopoietic Stem Cells Transplantation Chinese Huang Hui-qiang et al. Journal of Cancer Research(CJC) 2002 14(1):50-53

Preliminary outcome of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin’s lymphoma :single institution experience Bufei Wang ,Huiqiang Huang The Chinese-German Journal of Clinical Oncology 2006 Dec Vol5 Num 6（402）

Phase II clinical trial of Lopaplatin in the treatment of solid malignancies Jiang wen- qi Lin Tong-yi Huang Hui-qiang et al : International Journal of Modern Cancer Therapy 1999，33:312-5

Novantrone:A phase II trial in the treatment of advanced nasopharyngeal carcinoma in the People’s Republic of China Z.Z. Guan, H.Q. Huang , R. Rastogi Proceedings of American Society of Clinical Oncology(ASCO) 1993 : 12 (5) abstract 922

Dr. Feng Wang is currently a professor and vice director in the Department of Medical Oncology at Sun Yat-Sen University Cancer Center, Guangzhou, China. She has extensive experience and expertise in the field of gastrointestinal medical oncology and translation research in gastrointestinal cancers. Dr Wang sees more than 3,000 patients with gastrointestinal cancers annually and has initiated or participated in many investigator initiated and NMPA approved clinical trials. She presides over a number of research programs including the international (regional) cooperation and exchange program, and general program from the National Natural Science Foundation of China, the Doctoral Program of Higher Education of China, and has participated in several international cooperation, national and provincial level projects. Dr. Wang has published over 90 peer-reviewed articles, including some first author and corresponding author papers in renowned journals such as JAMA Oncology, Cell Research, Annals of Oncology, EMBO Mol Med, and Oncogene, and has been invited to present her research results at AACR, CSCO, Nature Conference, Chinese Congress of Oncology and other international conferences. She was awarded many prizes including the Second Prize of National Science and Technology Progress Award, First Prize of Chinese Medical Science and Technology Award, the First Prize of Guangdong Province Science and Technology Progress Award, the Outstanding Young Talents of Sun Yat-sen University Cancer Center and the New Stars of Science and Technology in Guangzhou etc. She holds many academic posts, including the Vice Director of Youth Committee of Professional Committee of Tumor Targeted Therapy, Chinese anti-cancer association and a Chairing Committee member of Chinese Society of Clinical Oncology etc. 

Sep 2008-Jun 2012
UT M.D. Anderson Cancer Center, PhD 

Jul 2008-Sep 2005
Sun Yat-sen University Cancer Center, MS

Sep 2000-Jul 2005
Jiangxi Medical College, Bachelor of Medicine

Selected publications
1. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH. JAMA Oncology. 2019.

2. The genomic landscape of small cell carcinoma of the esophagus. Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX, Xu RH. Cell Research. 2018.

3. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, Feng JF, Ba Y, Liu YP, Li W, Shu YQ, Jiang Y, Li Q, Wang JW, Wu H, Feng H, Yao S, Xu RH. Annals of Oncology. 2019.

4. AMPKα1 confers survival advantage of colorectal cancer cells under metabolic stress by promoting redox balance through the regulation of glutathione reductase phosphorylation. Wang YN, Lu YX, Liu J, Jin Y, Bi HC, Zhao Q, Liu ZX, Li YQ, Hu JJ, Sheng H, Jiang YM, Zhang C, Tian F, Chen Y, Pan ZZ, Chen G, Zeng ZL, Liu KY, Ogasawara M, Yun JP, Ju HQ, Feng JX, Xie D, Gao S, Jia WH, Kopetz S, Xu RH, Wang F. Oncogene. 2018.

5. Germline mutational profile of Chinese patients under 70 years old with colorectal cancer. Jiang TJ, Wang F, Wang YN, Hu JJ, Ding PR, Lin JZ, Pan ZZ, Chen G, Shao JY, Xu RH, Zhao Q, Wang F. Cancer Commun. 2020.

6. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, Huang JS, Shao Y, Zhu DQ, Ouyang YM, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH, Zhang DS. Mol Cancer. 2020.

7. Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers. Wu HX, Chen YX, Wang ZX, Zhao Q, He MM, Wang YN, Wang F, Xu RH. J Immunother Cancer. 2019. 

8. A circRNA signature predicts postoperative recurrence in stage II/III colon cancer. Ju HQ, Zhao Q, Wang F, Lan P, Wang Z, Zuo ZX, Wu QN, Fan XJ, Mo HY, Chen L, Li T, Ren C, Wan XB, Chen G, Li YH, Jia WH, Xu RH. EMBO Mol Med. 2019.

9. Designing gene panels for tumor mutational burden estimation: the need to shift from 'correlation' to 'accuracy'. Wu HX, Wang ZX, Zhao Q, Wang F, Xu RH. J Immunother Cancer. 2019.

10. Chemotherapy With or Without Anti-EGFR Agents in Left- and Right-Sided Metastatic Colorectal Cancer: An Updated Meta-Analysis. Wang ZX, Wu HX, He MM, Wang YN, Luo HY, Ding PR, Xie D, Chen G, Li YH, Wang F, Xu RH. J Natl Compr Canc Netw. 2019.

Updated March 2021

2008----present Associate professor. Medical Breast Cancer Department, Cancer Center, Sun Yat-Sen University. August 2004----2007 Attending Doctor and lecturer, Medical Oncology Department, Cancer Center, Sun Yat-Sen University. Secretary of Expert Panel in Good Clinical Practice Center, Cancer Center, Sun Yat-Sen University.Secretary of medical department, Cancer Center, Sun Yat-Sen University.Secretary of Expert Panel in Medical Record Administration, Cancer Center, Sun Yat-Sen University.

Journal Reviewer
2010 Chinese Journal of Cancer

2009 Chinese Journal of CancerJournal Editor

2009 Global oncology express

Honors and Awards
2007 The Best Service Award of Cancer Center, Sun Yat-Sen University

2006 Excellent Paper Awards, the Fourth Chinese Conference on Oncology.

1993 The Best Service Award of First hospital of Xu zhou Mineral Bureau

1992 The Third rank Scholarship of Yangzhou Medical College.

Associations and Memberships
Member of Chinese Society of Clinical Oncology (CSCO).

Member of Guangdong Provincial Anticancer Association (GDACA)

Professor Qingqing Cai has been engaged in clinical oncology work for more than 20 years, specializing in the area of clinical, translational, and basic research on lymphoma, nasopharyngeal carcinoma, head and neck squamous cell carcinoma. She served as the leader of the lymphoma Group of Guangdong Medical Association, and has won the "2020 People's Good Doctor" (Lymphoma) Outstanding Contribution Award”, the first batch of “Outstanding Young Medical Talents in Guangdong Province”, and other titles. In the past 5 years, she has published 17 articles as the corresponding author (or co-corresponding author) in prestigious journals including Blood, Leukemia, Clin Cancer Res, Signal Transduct Target Ther, etc., and presided over several national natural science foundations and provincial foundations. 

Specializes in clinical, transformation and basic research of lymphoma; and in clinical research on nasopharyngeal carcinoma, head and neck squamous cell carcinoma.

1. A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma patients undergoing non-anthracyline-based treatment: a retrospective, international, cohort study.Xiao-Peng Tian# ; Shu-Yun Ma# ; Ken H. Young# ; Choon Kiat Ong# ; Yan-Hui Liu# ; Zhi-Hua Li; Qiong-Li Zhai; Hui-Qiang Huang; Tong-Yu Lin; Zhi-Ming Li; Zhong-Jun Xia; Li-Ye Zhong; Hui-Lan Rao; Mei Li; Jun Cai; Yu-Chen Zhang; Fen Zhang; Ning Su; Peng-Fei Li; Feng Zhu; Zijun Y Xu-Monette; Esther Kam Yin Wong; Jeslin Chian Hung Ha; Lay Poh Khoo; Le Ai; Run-Fen Cheng; Jing Quan Lim; Sanjay de Mel; Siok-Bian Ng; Soon Thye Lim; Cai QQ*.Blood  2021.

2. Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: A multicenter study.Yuchen Zhang#; Shuyun Ma#;  Jun Cai#;Yu Yang#; Hongmei Jing#;Yuerong Shuang; Zhigang Peng; Bingzong Li; Panpan Liu1;  Zhongjun Xia; Yi Xia1; Yan Gao; Daoguang Chen; Jianyang Lin; Qihui Li; Shenghua Xu; Qingyuan Xu; Han; Zhang; Huiqiang Huang *;  Qingqing Cai*.Am J Hematol 2021.

3. Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma.Jun Cai# ; Panpan Liu# ; Huiqiang Huang# ; Yajun Li; Shuyun Ma; Hui Zhou; Xiaopeng Tian; Yuchen Zhang; Yan Gao; Yi Xia; Xuanye Zhang; Hang Yang; Lirong Li; Cai QQ*.Signal Transduction and Targeted Therapy 2020.

4. A CpG methylation classifier to predict relapse in adults with T-cell lymphoblastic lymphoma.Tian XP# ; Su N# ; Wang L# ; Huang WJ# ; Liu YH; Zhang X; Huang HQ; Lin TY; Ma SY; Rao HL; Li M; Liu F; Zhang F; Zhong LY; Liang L; Lan XL; Li J; Liao B; Li ZH; Tang QL; Liang Q; Shao CK; Zhai QL; Cheng RF; Sun Q; Ru K; Gu X; Lin XN; Yi K; Shuang YR; Chen XD; Dong W; Sun C; Sang W; Liu H; Zhu ZG; Rao J; Guo QN; Zhou Y; Meng XL; Zhu Y; Hu CL; Jiang YR; Zhang Y; Gao HY; He WJ; Xia ZJ; Pan XY; Hai L; Li GW; Song LY; Kang TB; Xie D* ; Cai QQ*.CLINICAL CANCER RESEARCH 2020.

5. A gene-expression-based signature predicts survival in adults with T-cell lymphoblastic lymphoma: A multicenter study  Running Title: A Gene Classifier to Predict Adult T-LBL Prognosis.Tian XP# ; Xie D# ; Huang WJ# ; Ma SY# ; Wang L; Liu YH; Zhang X; Huang HQ; Lin TY; Rao HL; Li M; Liu F; Zhang F; Zhong LY; Liang L; Lan XL; Li J; Liao B; Li ZH; Tang QL; Liang Q; Shao CK; Zhai QL; Cheng RF; Sun Q; Ru K; Gu X; Lin XN; Yi K; Shuang YR; Chen XD; Dong W; Sang W; Sun C; Liu H; Zhu ZG; Rao J; Guo QN; Zhou Y; Meng XL; Zhu Y; Hu CL; Jiang YR; Zhang Y; Gao HY; He WJ; Xia ZJ; Pan XY; Lan H; Li GW; Liu L; Bao HZ; Song LY; Kang TB; Cai QQ*.Leukemia 2020.

6. BRD2 induces drug resistance through activation of the RasGRP1/Ras/ERK signaling pathway in adult T-cell lymphoblastic lymphoma.Xiao-Peng Tian* Jun Cai* Shu-Yun Ma* Yu Fang* Hui-Qiang Huang  Tong-Yu Lin  Hui-Lan Rao Mei Li  Zhong-Jun Xia Tie-Bang Kang Dan Xie Qing-Qing Cai# .Cancer Communications 2020.

7. Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma.Tian XP# ; Huang WJ# ; Huang HQ# ; Liu YH; Wang L; Zhang X; Lin TY; Rao HL; Li M; Liu F; Zhang F; Zhong LY; Liang L; Lan XL; Li J; Liao B; Li ZH; Tang QL; Liang Q; Shao CK; Zhai QL; Cheng RF; Sun Q; Ru K; Gu X; Lin XN; Yi K; Shuang YR; Chen XD; Dong W; Sang W; Sun C; Liu H; Zhu ZG; Rao J; Guo QN; Zhou Y; Meng XL; Zhu Y; Hu CL; Jiang YR; Zhang Y; Gao HY; He WJ; Xia ZJ; Wu CL; Zhang MY; Wang HY; Xie D* ; Cai QQ* .Leukemia 2019.

8. Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal natural killer T-cell lymphoma.Peng RJ# ; Han BW# ; Cai QQ# ; Zuo XY; Xia T; Chen JR; Feng LN; Lim JQ; Chen SW; Zeng MS; Guo YM; Li B; Xia XJ; Xia Y; Laurensia Y; Chia BKH; Huang HQ; Young KH; Lim ST; Ong CK* ; Zeng YX* ; Bei JX* ;.Leukemia 2019.

9. IL-2R alpha up-regulation is mediated by latent membrane protein 1 and promotes lymphomagenesis and chemotherapy resistance in natural killer/T-cell lymphoma. Wang L#* ; Bi XW# ; Zhu YJ; He YZ; Lai QY; Xia ZJ; Cai QQ*. Cancer Communications 2018.

10. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study. Hu, Li-Yang; Xu, Xiao-Lu; Rao, Hui-Lan; Chen, Jie; Lai, Ren-Chun; Huang, Hui-Qiang; Jiang, Wen-Qi; Lin, Tong-Yu; Xia, Zhong-Jun; Cai QQ*, Chinese Journal of Cancer, 2017.

Updated November 2021

2010.08 -2010.12    Clinical observer, Breast Cancer Medicine service

Memorial Sloan-Kettering Cancer Center (MSKCC), New York, USA

2007.01-2012.12   Associate professor,

Department of medical oncology,

Cancer center of Sun Yat-sen University, China

2004.07- 2006.12   Lecturer & Attending Physician,

Department of medical oncology,

Cancer center of Sun Yat-sen University, China

1998.07 -2001.08    Lecturer & attending physician,

Affiliated hospital of Xuzhou Medical College, China

1992.07 -1995.08    Resident physician,

Affiliated hospital of Xuzhou Medical College, China

1. Familiar with medical oncology and phase I, II, III Clinical trials

2. Cell culture and purification of protein. 

3. In vitro and in vivo study of anti-cancer drugs

4. Molecular biological techniques

2001-2004 Ph.D. in Medical Oncology, Sun Yat-sen University, China

1995-1998 M.S. in Medical Oncology, Henan Medical University, China 

1987-1992 M.D. in Clinical Medicine, Xuzhou Medical College, China

1.       Fu L, Shi K, Wang J, ChenW, Shi D, Tian Y, Guo W, Yu W, Xiao X, Kang T, Wang S, Huang W, Deng W. TFAP2B overexpressioncontributes to tumor growth and a poor prognosis of human lung adenocarcinomathrough modulation of ERK and VEGF/PEDF signaling. Mol Cancer,2014,13:89  (corresponding author)

2.       Chen W, Qin L, Wang S, Li M, Shi D, Tian Y, Wang J, FuL, Li Z, Guo W, Yu W, Yuan Y, Kang T, Huang W, Deng W. CPSF4 activates telomerasereverse transcriptase and predicts poor prognosis in human lungadenocarcinomas. Mol Oncol. 2014May;8(3):704-716  (correspondingauthor)

3.       ZENG Yin-duo, XU Fei, QIN Tao,YANG Yan-hua,LIAO Yu-ting,Qin Ge,Wang Shu-sen. Toremifene inPostmenopausal Operable Patients with Luminal Subtype of Breast Cancer asCompared with Tamoxifen:A Retrospective Study in China. Chin J Bases ClinGeneral Surg,  2014,21( 5):555-561(correspondingauthor)

4.       Ma hongmin,Hu lingyu, Wang shusen.Diagnosis and Treatment for Occult Breast Cancer. Chin J BasesClin General Surg, 2014, 21( 5):544-548(corresponding author)　

5.       Qin T, Yuan ZY, PengRJ,Zeng YD,Shi YX, Teng XY,Liu DG, Bai B, WangSS .Efficacy andtolerability of toremifene and tamoxifen therapy in premenopausal patients withoperable breast cancer: a retrospective analysis. Curr Oncol,2013, 20(4):1-9  (correspondingauthor)

6.        Qin T, Yuan ZY, Peng RJ ,Shi YX, Teng XY,LiuDG, Bai B, Wang SS .HER2-positive breast cancer patients receivingtrastuzumab treatment obtain prognosis comparable with that ofHER2-negativebreast cancer patients. Onco Targets and Therapy.2013,6:341-47   (corresponding author)

7.       QIN Tao, YUAN Zhong-yu, PENGRou-jun, BAI Bing, SHI Yan-xia, TENG Xiao-yu, LIU Dong-geng, WANG Shu-sen. Efficacy and Safety of Toremifene in Young Patients with LuminalSubtype Early Breast Cancer： A Retrospective Study. JOURNAL OF SUN YAT-SEN UNIVERSITY（MEDICAL SCIENCES）,2013,34(3):402-406(corresponding author)

8.       Fu ly, Chen WB, Guo W, WangJS, Tian Y, Shi DB, Zhang XH,Qiu HJ, Xiao XS, Kang TB, Huang WL, Wang SS,Deng WG.Berberine Targets AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF andCytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth. PIOS ONE,2013,8(7):1-13  (correspondingauthor)

9.       Gu WG, Huang Y, YuanZY, Peng RJ, Luo HT, He ZR, Wang SS. ZD1839 and cisplatin aloneor in combination for treatment of a nasopharyngeal carcinoma cell line andXenografts. Asian Pac J Cancer Prev. 2013;14(3):1787-90 (correspondingauthor)

10.   Wangbing Chen, Wei Guo, Mei Li, Dingbo Shi, Yun Tian, Zhenlin Li,Jingshu Wang, Lingyi Fu, Xiangsheng Xiao, Quentin Qiang Liu, Shusen Wang, Wenlin Huang, Wuguo Deng. Upregulation of cleavageand polyadenylation specific factor 4 in lung adenocarcinoma and its criticalrole for cancer cell survival and proliferation. PLoS One. 2013;8(12):e82728 (corresponding author)

11.    Wang S, Shi Y,Yuan Z, Wang X, Liu D, Peng R, Teng X, Qin T, Peng J, Lin G, Jiang X. ClassicalCMF regimen as adjuvant chemotherapy for triple-negative breast cancer may bemore effective compared with anthracycline or taxane-based regimens. Med Oncol.2012,29:547-553 (first author)

12.    He J, Peng R, Yuan Z, Wang S, Peng J, Lin G, Jiang X, Qin T. Prognostic value of androgenreceptor expression in operable triple negative breast cancer: A retrospectiveanalysis based on a tissue microarray. Med Oncol 2012,29:406-410

13.     Liu D, He J,Yuan Z, Wang S, Peng R, Shi Y, TengX, Qin T. EGFR expression correlates with decreased disease-free survival intriple negative breast cancer: A retrospective analysis based on a tissuemicroarray. Med Oncol. 2012,29:401-405

14.   Shi YX, Tan YT,Yuan ZY, Wang SS, Peng RJ, An X, CaoY, Jin Y, Cai XY, Sun YL, Teng XY, Liu DG. Comparison of overall survivalbetween the early use and delayed use of Trastuzumab therapy groups: aretrospective analysis of 128 patients with HER-2-positive advanced breast cancer.Med Oncol 2012,29:39-47

15.   Shi YX, Xia Q,Peng RJ, Yuan ZY, Wang SS, An X, CaoY, Tan YT, Jin Y, Cai XY, Sun YL, Teng XY, Liu DG, Jiang WQ. Comparison ofclinicopathological characteristics and prognoses between bilateral andunilateral breast cancer. J Cancer Res Clin Oncol. 2012 ,138:705-714

16.    Wang x, Wang SS,Peng RJ, Qin T, Shi YX, Teng xy, Chen wq, Liu DG,  Yuan ZY. Interaction of coping styles andpsychological stress on anxious and depressive symptoms in Chinese breastcancer patients. Asian Pacific J Cancer Prev 2012; 13:1645-1649. （IF：1.24）

17.   PengR, Wang S, Shi Y, Liu D, Teng X, QinT, Zeng Y, Yuan Z. Patients 35 years old oryounger with operable breast cancer are more at risk for relapse and survival:A retrospective matched case-control study. Breast. 2011; 20: 568-573.（IF：2.089）

18.    Liu DG, WangSS, Peng RJ, Qin T, Shi YX, Teng XY, Wang X, Chen WQ, Yuan ZY. Interaction of Social Support andPsychological Stress on Anxiety and Depressive Symptoms in Breast CancerPatients. Asian Pacific J Cancer Prev 2011; 12:2523-2529. （IF：1.24）

19.   Bing Bai, Shusen Wang et al. Clinical Featuresand Survival Analysis of Different  Subtypesof   Patients with Breast Cancer BrainMetastases. Chinese Journal of Cancer, 2010,29(4): 453-461. (corresponding author)

20.   Qin jianyong Wang shusen,YIN CHUANZHONG The legaland ethic issues in operating medical information service website. JOURNAL OFMEDICAL INFORMATICS,2010,31(8):52-55

21.   Yuan zhongyu,Shusen Wang, et al.  Clinical Characteristics and Prognosis ofTriple-Negative Breast Cancer: A Report of 305 Cases. Chinese Journal ofCancer, 2008, 27(6)..

22.   Yuan zhongyu,Shusen Wang, et al. Clinical characteristics and prognosis ofdifferent subtypes of breast cancer Chinese Journal of Oncology.  2008 ,30(6):456-61

23.   Fu xiaohong, Wang shusen, Huang yan,el al. Prognostic significance of CD20expression in Hodgkin and Reed-sternberg cells of classical hodgkin’s lymphoma.Chinesr journal of cancer 2008,27(11):1197-1203

24.   CAO Ya –Bing, WANG Shu-Sen, HUANG Hui-Qiang et al.Primary Breast Lymphoma —A Report of 27 Cases withLiterature Review Chinese Journalof Cancer, 2007, 26( 1) : 84- 89

25.   Xiao Jian, Wang Shusen, Huang Yan et al.  Expression of CD117 and PDGFRa in ExtranodularNK/T Cell Lymphoma (Nasal Type) .Chinese Journal of Clinical Oncology2,007 34(11):615-617

26.   QIU Miao-Zhen, XUFei, WANG Shu-Sen et al.Responses of 109 Adult Soft Tis sue Sarcoma Patientsto Chemotherapy .Chinese Journal of Cancer, 2007, 26( 12) : 1344- 1349

27.    Shusen Wang, Zhongzhen Guan, et al. The Significance of EGFR and p-ERK Expressionin Nasopharyngeal Carcinoma，Chinese Journal of Oncology.2006,28(1).

28.    Shusen Wang, Zhongzhen Guan, et al. The Significance of c-Fos, and Cyclin-D1Expression in Nasopharyngeal Carcinoma，Chinese Journalof Clinical Oncology，2005,32,(6)

29.    Shusen Wang, Zhongzhen Guan, et al. In vivo Study of Epidermal Growth FactorReceptor-Selective Tyrosine Kinase Inhibitor Gefitinib on NasopharyngealCarcinoma. Chinese Journal of Cancer, 2004,23(11s).

30.   Yanqun Xiang, Shusen Wang, et al Prognostic Value ofSurviving and Living in Nasopharyngeal Carcinoma, The Laryngoscope, 116(1).

31.    Shusen Wang, Zhongzhen Guan, et al. Angiogenesis Modulator and Tumor. ChineseJournal of Medicine.2004, 4(1): 24-29.

32.    Shusen Wang, Tongyu Lin, et al. Anti-Cancer Therapy Targeting EGFR. ChineseJournal of Cancer Palliative Medicine. 2003,2(4): 239-242.

33.    Shusen Wang, Wenqi Jiang. Improving the Level of Clinical Study According toGood Clinical Practice. National Medical Journal of China.2003,83(3):179-180.

34.    Shusen Wang , Ruilin Wang, et al. Study on the Purification of AngiogenesisInhibitor from Shark Cartilage and its Biological Characteristics. HenanJournal of Oncololgy.1999, 12(3): 179-181.

35.    Shusen Wang, Lisong Tan, et al. A Study on the Method Using 1H11 EndothelialCells to Assay Angiogenesis Inhibitor. ACTA Academiae Medicinae Xuzhou. 1998,18 (3): 176-178.

36.   Jinchuan Zhang, Shusen Wang, et al. Detecting TumorSpecific Growth Factor in Patients with Chemotherapy. Academiae MedicinaeXuzhou.2001, 21(2): 116-117.

37.   Desheng liu, Shusen Wang et al. How to Improve theEffect and Safety of Three-Step Method of Analgesia. Chinese Journal ofClinical Oncology and Recovery.1999, 6 (5): 77-79. 

Clinical and translational research for lymphoma, head and neck cancer (including nasopharyngeal cancer). Especially development of novel drugs, prognostic and predictive markers for these tumors, conduct of phase I and II clinical trials to test drugs.

Bachelor of Medicine, Sun Yat-Sen University of Medical Sciences, China, 1992-1997

Ph.D. in Oncology, Sun Yat-sen University, China, 1997-2002

Post Doctorate, Sun Yat-sen University Cancer Center, China, 2002-2004

Visiting scholar, Oncology Institute of Southern Switzerland, Switzerland, 2011-2012

Selected publications

1. Metronomic combination chemotherapy using everolimus and etoposide for the treatment of non-Hodgkin lymphoma. Wu K, Sun XQ, Wang CQ, Gao TX, Sun P, Wang Y, Jiang WQ, Li ZM#, Huang JJ#. Cancer Med 2020

2. High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China. Chen C, Sun P, Cui J, Yan SM, Chen H, Xia Y, Bi XW, Liu PP, Wang Y, Yang H, Nie M, Zhang XW, Jiang WQ, Li ZM#. Cancer Med 2019

3. Mutation Profiling of Malignant Lymphoma by Next-Generation Sequencing of Circulating Cell-Free DNA. Sun P*, Chen C*, Xia Y*, Wang Y, Liu PP, Bi XW, Shao YW, Ou QX, Wu X, Yang H, Nie M, Zhang XW, Li ZM#, Jiang WQ#. Journal of Cancer 2019

4. Trends in Survival of Patients With Primary Gastric Diffuse Large B-Cell Lymphoma: An Analysis of 7051 Cases in the SEER Database. Liu PP, Xia Y, Bi XW, Wang Y, Sun P, Yang H, Li ZM#, Jiang WQ#. Dis Markers 2018

5. A Comparison of R-EPOCH and R-CHOP as a First-Line Regimen in De Novo DLBCL Patients With High Ki-67 Expression in a Single Institution. Huang JJ, Xia Y, Wang Y, Liu PP, Bi XW, Sun P, Lin TY, Jiang WQ, Li ZM#. Oncotarget, 2016

6. Racial Patterns of Patients With Primary Mediastinal Large B-cell Lymphoma: SEER Analysis. Liu PP*, Wang KF*, Xia Y, Bi XW, Sun P, Wang Y, Li ZM#, Jiang WQ#. Medicine (Baltimore) 2016

7. High risk of deep vein thrombosis associated with peripherally inserted central catheters in lymphoma. Zhang X*, Huang JJ*, Xia Y*, Li CF, Wang Y, Liu PP, Bi XW, Sun P, Lin TY, Jiang WQ, Li ZM#. Oncotarget, 2016

8. Consolidative treatment after salvage chemotherapy improves prognosis in patients with relapsed extranodal natural killer/T-cell lymphoma. Nie M*, Bi XW*, Zhang WW*, Sun P, Xia Y, Liu PP, Huang HQ, Jiang WQ, Li ZM#. Sci Rep 2016

9. Effect of Rituximab on Adult Burkitt's Lymphoma: A Systematic Review and Meta-Analysis. Nie M*, Wang Y*, Bi XW, Xia Y, Sun P, Liu PP, Li ZM#, Jiang WQ#. Ann Hematol 2016

10. Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt’s lymphoma. Wei WX*, Huang JJ*, Li WY, Zhang X, Xia Y, Jiang WQ, Fan W#, Li ZM#. Chin J Cancer 2015

11. Expression of BAFF-R, but Not BAFF, Is an Independent Prognostic Factor in Diffuse Large B-cell Lymphoma Patients Treated With R-CHOP. Wang Y*, Li YJ*, Jiang WQ, Rao HL, Huang JJ, Xia Y, Bi XW, Sun P, Huang HQ, Lin TY, Guan ZZ, Li ZM#. Ann Hematol, 2015

12. Radiotherapy and PGEMOX/GELOX regimen improved prognosis in elderly patients with early-stage extranodal NK/T-cell lymphoma. Bi XW*, Xia Y*, Zhang WW, Sun P, Liu PP, Wang Y, Huang JJ, Jiang WQ, Li ZM#. Ann Hematol 2015

13. Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma in the Elderly: A Matched Case-Control Analysis. Song CG*, Huang JJ*, Li YJ*, Xia Y, Wang Y, Bi XW, Jiang WQ, Huang HQ, Lin TY, Li ZM#. PLoS One 2015

14. Treatment outcome of patients with advanced stage natural killer/T-cell lymphoma: elucidating the effects of asparaginase and postchemotherapeutic radiotherapy. Bi XW*, Jiang WQ*, Zhang WW, Huang JJ, Xia Y, Wang Y, Sun P, Li ZM#. Ann Hematol 2015

15. High APRIL but not BAFF serum levels are associated with poor outcome in patients with follicular lymphoma. Li YJ*, Li ZM*, Xia ZJ, Li S, Xia Y, Huang HQ, Huang JJ, Yi PY#, Jiang WQ#. Ann Hematol 2015

16. Prognostic Value of Interim and Posttherapy 18F-FDG PET/CT in Patients with Mature T-Cell and Natural Killer Cell Lymphomas. Ya-Jun Li*, Li ZM*, Xi-Ya Xia*, Huang HQ, Xia ZJ, Lin TY, Li S, Xia Y, Cai XY, Jiang WQ#. J Nucl Med 2013

17. Absolute Lymphocyte Count Is a Novel Prognostic Indicator in Extranodal Natural killer/T-cell Lymphoma, Nasal Type. Huang JJ*, Jiang WQ*, Lin TY, Huang Y, Xu RH, Huang HQ, Li ZM#. Ann Oncol 2011

18. Beclin 1 expression: A predictor of prognosis in patients with extranodal natural killer T-cell lymphoma, nasal type. Huang JJ, Li HR, Huang Y, Jiang WQ, Xu RH, Huang HQ, Lv Y, Xia ZJ, Zhu XF, Lin TY#, Li ZM#. Autophagy 2010

Updated May 2020

Selected Publications
1. Hua X*, Bi XW*, Zhao JL*, Shi YX*, Lin Y, Wu ZY, Zhang YQ, Zhang LH, Zhang AQ, Huang H, Liu XM, Xu F, Guo Y, Xia W, Hong RX, Jiang KK, Xue C, An X, Zhong YY, Wang SS*, Huang JJ*, Yuan ZY*. Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002).  Clin Cancer Res. 2022; 28(4):637-645.

2. Wang X*, Wang SS*, Huang H, Cai L, Zhao L, Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH, Ke YL, Wang XM, Liu XM, Chen QJ, Zhang AQ, Xu F, Bi XW, Huang JJ, Li JB, Pang DM, Xue C, Shi YX, He ZY, Lin HX, An X, Xia W, Cao Y, Guo Y, Su YH, Hua X, Wang XY, Hong RX, Jiang KK, Song CG, Huang ZZ, Shi W, Zhong YY, Yuan ZY*; South China Breast Cancer Group (SCBCG). Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial. JAMA. 2021; 325(1):50-58. 

3. Su Y*, Huang J*, Wang S, Unger JM, Arias-Fuenzalida J, Shi Y, Li J, Gao Y, Shi W, Wang X, Peng R, Xu F, An X, Xue C, Xia W, Hong R, Zhong Y, Lin Y, Huang H, Zhang A, Zhang L, Cai L, Zhang J, Yuan Z*. The Effects of Ganglioside-Monosialic Acid in Taxane-Induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial. J Natl Cancer Inst. 2020;112(1):55-62.

4. Su Y*, Zhang Y*, Hua X, Huang J, Bi X, Xia W, Wang X, Huang Z, Song C, Zhong Y, Shi Y, Wang S; Fan W*, Yuan Z*. High-dose tamoxifen in high-hormone-receptor-expressing advanced breast cancer patients: a phase II pilot study. Adv Med Oncol. 2021; 13: 1–9.

5. Duan FF, Li JP, Huang JJ, Hua X, Song CG, Wang L, Bi XW, Xia W, Yuan ZY. Establishment and Validation of Prognostic Nomograms Based on Serum Copper Level for Patients With Early-Stage Triple-Negative Breast Cancer.  Front Cell Dev Biol. 2021;9:770115.

6. Hua X*, Huang X*, Huang ZZ*, Song CG, Deng JP, Long ZQ, Lin HX, Yuan ZY*. Establishment of prognostic nomograms based on skeletal muscle index and serum biomarker in breast cancer patients receiving radiotherapy. Clin Transl Med. 2020;10(2):e115.

7. Wang X*, Bi X*, Huang Z*, Huang J, Xia W, Shi W, Yuan Z*. The prognostic value of androgen receptor (AR) in HER2-enriched metastatic breast cancer. Endocr Relat Cancer. 2020; 27:199-208.

8. Wang X*, Li J*, Shi W, Huang Z, Xia W, Huang J, Su Y, Wang S, Shi Y, Bi X*, Yuan Z*. Efficacy of Moxifloxacin plus Treatment of Physician's Choice in Patients with Metastatic Breast Cancer. Oncologist. 2020; 25(10):e1439-45.

9. Xiong Z*, Ye L*, Zhenyu H*, Li F, Xiong Y, Lin C, Wu X, Deng G, Shi W, Song L, Yuan Z*, Wang X*. ANP32E induces tumorigenesis of triple-negative breast cancer cells by upregulating E2F1. Mol Oncol. 2018; 12(6):896-912.

10. Cui Y*, Ma W*, Lei F*, Li Q, Su Y, Lin X, Lin C, Zhang X, Ye L, Wu S, Li J, Yuan Z*, Song L*. Prostate tumour overexpressed-1 promotes tumourigenicity in human breast cancer via activation of Wnt/β-catenin signalling.  J Pathol. 2016;239:297–308.

Updated June 2022

2000/08-2004/08   
Department of respiration medicine, Affiliated hospital of Guilin Medical College, Resident   and  attending physician

2004/09-2007/06   
Department of MedicalOncology, Cancer center of Sun Yat-sen University,Master of oncology

2007/07-2010/07 
Department of Medical Oncology, Cancer center of Sun Yat-senUniversity, Oncology training Physician

2010/08-Present   
Department of Medical Oncology, Cancer center of Sun Yat-sen University, Attending Physician

Clinical and basic research inmedical oncology and translational medicine,especially in diagnosis and therapy for the gastrointestinal tumor.

1995/09-2000/07    Faculty of Clinical medicine in Guangxi Medical  University, Bachelor of medicine

2004/09-2007/06    Department of Medical Oncology, Cancer center of Sun Yat-sen University, Master ofoncology

2007/07-2010/07    Department of Medical Oncology, Cancer center of  Sun Yat-senUniversity, Oncology training Physician

2012.9-Present       PhD candidate

1.       Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P, Xu RH. Overexpression of the circadian clock gene bmal1increases sensitivity to oxaliplatin in colorectal cancer. Clin Cancer Res. 2014 Feb 15;20(4):1042-52.

2.       Wang DS, Luo HY, Qiu MZ, Wang ZQ, Zhang DS, Wang FH, Li YH, Xu RH.Comparison of the prognostic values of various inflammation based factors inpatients with pancreatic cancer. Med Oncol. 2012Dec;29(5):3092-100.

3.        Luo HY, Wang ZQ, Wang FH, Qiu MZ, Teng KY, RuanDY, He YJ, Li YH, Xu RH. Phase 2 study of capecitabine and irinotecancombination chemotherapy (modified XELIRI regimen) in patients with advancedgastric cancer. Am J Clin Oncol. 2011 Dec;34(6):555-60.

4.       Qiu MZ, Wang ZQ, Luo HY, Zhang DS, Zhou ZW, Li YH, JiangWQ, Xu RH. Prognostic analysis in node-negative gastric cancer patients inChina.Tumour Biol. 2011 Jun;32(3):489-92.

5.       Li FH, Shen L, Li ZH, Luo HY, Qiu MZ, Zhang HZ, Li YH, XuRH.Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectalcancer. World J Gastroenterol. 2010 Dec 14;16(46):5881-8.

6.       Qiu MZ, Han B, Luo HY, Zhou ZW, Wang ZQ, Wang FH, LiYH, Xu RH. Expressions of hypoxia-inducible factor-1α and hexokinase-II ingastric adenocarcinoma: the impact on prognosis and correlation toclinicopathologic features.Tumour Biol. 2011 Feb;32(1):159-66.

7.        Luo HY, Wei W, Shi YX, Chen XQ, Li YH, Wang F, QiuMZ, Li FH, Yan SL, Zeng MS, Huang P, Xu RH.Cetuximab enhances the effect ofoxaliplatin on hypoxic gastric cancer cell lines.Oncol Rep. 2010Jun;23(6):1735-45.

8.        Luo HY, Xu RH, Wang F, Qiu MZ, Li YH, Li FH, ZhouZW, Chen XQ.Phase II trial of XELOX as first-line treatment for patients withadvanced gastric cancer. Chemotherapy. 2010;56(2):94-100.

9.       Li YH, Luo HY, Wang FH, Wang ZQ, Qiu MZ, Shi YX, Xiang XJ, Chen XQ, He YJ,Xu RH.Phase II study of capecitabine plus oxaliplatin (XELOX) as first-linetreatment and followed by maintenance of capecitabine in patients withmetastatic colorectal cancer.J Cancer Res Clin Oncol. 2010 Apr;136(4):503-10. 

1994-1997 Sun Yat-sen University Cancer Center, M.S,Medical Oncology

1986-1991  BenBu medical college, B.S, Clinical Medicine

Postgraduate Training

2011-Present  Chief Physician, Department of MedicalOncology, Cancer Center, Sun Yat-sen University, Guangzhou , Guangdong

2009  Observer, Medical Oncology, Clinic, Rochester, Minnesota, USA

2007  Observer, Medical Oncology, Paul Brouss Hospital，France

2005-2011  Associated Professor, Department of Medical Oncology, Cancer Center, Sun Yat-senUniversity, Guangzhou, Guangdong

2000-2005  Attending Physician, Department of Medical Oncology, Cancer Center, Sun Yat-senUniversity, Guangzhou, Guangdong

1997- 2000  Resident, Department of Medical Oncology, Cancer Center, Sun Yat-sen University,Guangzhou , Guangdong

1.       An X, Li YH (Corresponds).MET amplification is not rare and predictsunfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer afterchemotherapy. Cancer. 2014 Mar 1; 120(5):675.

2.       An X, Li YH (Corresponds).Serum HER 2 extracellular domain level is correlated with tissue HER 2status in metastatic gastric orgastro-oesophageal junction adenocarcinoma.PLoS One. 2013 May 14;8(5):e63458.

3.       Chen C, Li YH (Corresponds). Polymorphisms in ERCC1 C8092A predict progression-free survival inmetastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-basedchemotherapy. Cancer Chemother Pharmacol. 2013 Aug; 72(2):315.

4.       Chen C, Li YH (Corresponds).Tripletcombination with paclitaxel, cisplatin and 5-FU is effective in metastaticand/or recurrent nasopharyngeal carcinoma.Cancer Chemother Pharmacol.2013Feb; 71(2):371.

5.       Chen C, Li YH (Corresponds).Salvagegemcitabine- vinorelbine chemotherapy in patients with metastaticnasopharyngeal carcinoma pretreated with platinum- based chemotherapy. Oral Oncol.2012 Nov; 48(11):1146.

6.       Li YH, Wang F,et al. EGFR FISH Pattern of Chromosome 7Disomy Predicts Resistance to Cetuximab in KRAS Wild-type Metastatic ColorectalCancer Patients. Clin Cancer Res.2011; 15; 17(2):382.

7.       An X, Li YH (Corresponds).PlasmaEpstein-Barr virus DNA level strongly predicts survival in metastatic/recurrentnasopharyngeal carcinoma treated with palliative chemotherapy. Cancer. 2011;15; 117(16):3750.

8.       An X, Li YH (Corresponds).Elevatedneutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngealcarcinoma. Tumor Biol.2011; 32(2):317.

9.       Wang FH, Li YH (Corresponds).Phase IIstudy of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin asfirst-line chemotherapy in patients with advanced gastric cancer. Am J ClinOncol. 2011; 34(4):401.

10.   Yu Hong Li, HuiYan Luo, et al. Phase II study of capecitabine plusoxaliplatin(XELOX) as first-line treatment and followed by maintenance ofcapecitabine in patients with metastatic colorectal cancer. J Cancer Res ClinOncol.2010; 136(4):503.

11.   An X, Ding PR, Li YH (Corresponds).Carcinoembryonic antigen surge in metastatic colorectal cancer patientsresponding to irinotecan combination chemotherapy. Biomarkers.2010; 15(3):243.

12.   Li YH, Hu CF, etal. Elevated Expressions of Survivin andVEGF Protein are Strong Independent Predictors of Survival in Advanced NasopharyngealCarcinoma. J Transl Med. 2008; 3; 6(1):1.

13.   Li YH, Wang FH,et al. Phase II study of capecitabine andcisplatin combination as first-line chemotherapy in Chinese patients withmetastatic nasopharyngeal carcinoma. Cancer Chemother Pharmacol. 2008; 62(3):539.

14.   He YF, Li YH(Corresponds) et al. Theeffectiveness of lamivudine in preventing hepatitis B viral reactivation inrituximab-containing regimen for lymphoma. Ann Hematol. 2008; 87(6):481.

15.   Luo HY, Li YH,et al. Efficacy of CPT-11 combined 5-FU/CF(FOLFIRI) regimen on advanced colorectal cancer. Ai Zheng. 2007; 26(8):905.

16.   Li YH, He YF, et al. Lamivudineprophylaxis reduces the incidence and severity of hepatitis in hepatitis Bvirus carriers who receive chemotherapy for lymphoma. Cancer. 2006, 15;106(6):1320-1325.

17.   He YF, Li YH (Correspondence), et al.Prognostic analysis of 220 colorectal cancer patients with synchronous livermetastases. Ai Zheng. 2006; 25(9):1153.

18.   Wang FH, Li YH, et al. PhaseI Clinical Trial of Intravenous Recombinant Human Lymphotoxin-α Derivative. Aizheng.2006; 26(4):501.

19.   Xiang XJ,He YJ ,Li YH .Clinical Significance of SurvivinExpression in Peripheral T-cell Lymphoma. Ai zheng.2006; 25(6):758.

20.   Li YH, He YF, et al. Clinical analysisof liver damage of 116 malignant lymphoma patients with chronic HBV infectionafter cytotoxic chemotherapy. Ai zheng.2005, 24(12):1507.

21.   Li YH, Shao JYet al. The clinical significance of MMP-9CD44v6 protein expression in nasopharyngeal carcinoma. Ai zheng. 2004; 31(20):1153.

22.   Li YH, Shao JY, etal. Clinical Significance of Quantitative Analysis of plasma Epstein-Barr virusDNA Concentration in nasopharyngeal carcinoma. Chinese J of Clinical Oncology. 2004; 31(8)421.

23.   Li YH, Shao JY, et al.Clinical significanceof quantitative analysis of serum VEGF, CD44s, and MMP-3 protein in nasopharyngealcarcinoma. Ai zheng. 2004; 23(9):1060.

24.   He YF, Li YH, Huang HQ,et al.Prognosis analysis of 53 cases with primary intestinal Non- Hodgkin's lymphoma.Ai zheng. 2005, 24(4):475.

25.   Shao JY, Li YH, et al. Comparison ofplasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/viruscapsid antigen antibody titers in patients with nasopharyngeal carcinoma.Cancer. 2004; 15; 100(6):1162.

26.   Shao JY, Li YH, et al. High frequencyof common deletion (4981 bp) in mitochondrial DNA in nasopharyngeal carcinomaand its correlation with patient age and clinical stages. Cancer Biol Ther.2004; 3(12):1270.

27.   Li YH, Shao JY, et al. Quantitativeanalysis of plasma Epstein-Barr virus (EBV) DNA for monitoring of recurrenceand metastasis in nasopharyngeal carcinoma patients after radiotherapy. Aizheng. 2003; 22(6):645.

28.   Li YH, Jiang WQ, et al. Clinicalanalysis of 75 patients with nasopharyngeal non-Hodgkin's lymphoma. Ai zheng.2003; 22(4):401.

29.   Shao JY, Li YH, et al. High frequencyloss of heterozygosity on the long arms of chromosomes 13 and 14 innasopharyngeal carcinoma in Southern China. Chinese Medical Journal. 2002;115(4):571.

30.   Shao JY, Li YH, et al. Deletion ofchromosomes 9p and 17 associated with abnormal expression of p53, p16/MTS1 andp15/MTS2 gene protein in hepatocellular carcinomas. Chinese Medical Journal,2000; 113(9):817.  

31.   Zhang DS,Din Y, Li YH, et al. PredictiveSignificance of Serum 90K/Mac-2BP on Chemotherapy Response in Non-Hodgkin'sLymphoma. Ai zheng. 2005; 24(8):1006.

32.   Xiang XJ,He YJ ,Li YH .PrognosisAnalysis of 53 Cases with Primary Intestinal Non- Hodgkin's Lymphoma. Ai zheng.2004; 23(4):443.

33.   Shao JY, Gao HY, Li YH et al.Quantitative detection of common deletion of mitochondrial DNA inhepatocellular carcinoma and hepatocellular nodular hyperplasia. World JGastroenterol. 2004; 10(11):1560.

34.   Li YH, Jiang WQ, et al. Preliminarystudy on DHAP regimen for patients with relapsed and refractory non-Hodgkin'slymphoma: Ai zheng. 2002; 21(8):900.

35.   Huang HQ, Zhou ZM, Li YH, et al. Preliminaryresults of Ifosfamide and Doxorubicin regimen in treatmentof patients with recurrentand metastatic nasopharyngeal carcinoma. Ai zheng.2002, 21(4):409.

36.   Li YH, Rao HL,et al. Anaplasticlarge cell lymphoma—review and 20 cases report. Ai zheng. 2000; 19(9):914.

37.   Li YH, He YJ, et al. Clinical trialof 5FU/CF and carboplatin combination chemotherapy in patients with advancednasopharyngeal carcinoma (NPC). Ai zheng.1999; 18(3):295.

38.   Li YH, Xu RH,et al. Apilot study of 5-FU circadian pharmacokinetics in patients with nasopharyngealcarcinoma .Ai zheng.1999;18(6):694.

39.   Guan zz,Chen RQ,Xu GC, Li YH, et al. Gemcitabinein the treatment of advanced nonsmallcell lung cancer. Ai zheng.1999; 18(3);241.

Dr. Ying Liang is an Associate professor of Department of Medical Oncology, Sun Yat-sen University Cancer Center. Dr. Liang obtained her MD and PhD degree at Sun Yat-sen University of Medical Sciences in 2000 and 2009, respectively. She has been working in Sun Yat-sen University Cancer Center since 2002. From 2013 to 2014, she studied at Stanford Cancer Institute, Stanford University School of Medicine. Dr. Liang’s major research interests are medical treatment and research on thoracic malignancies (non-small cell lung cancer, small cell lung cancer, thymic malignancy, malignant pleural mesothelioma, esophageal cancer, etc.), lymphoepithelioma-like carcinoma and nasopharyngeal carcinoma. Dr. Liang has authored or coauthored more than 40 peer-reviewed articles in scientific journals including Cancer, British Journal of Caner, Annals of Surgical Oncology, Lung Cancer and Clinical Lung Cancer, ect. She has participated in many international randomized control studies, SFDA approved clinical trials, investigator initiated trials and phase I trials. Dr. Liang is a member of International Association for the Study of Lung Cancer (IASLC), International Thymic Malignancies Interest Group (ITMIG) Dr. Liang serves on the editorial boards of Translational Lung Cancer Research, and the invited reviewer of Journal of Thoracic Oncology, Lung Cancer, Journal of Thoracic Disease, BMC Case Report.

Work experience

Jul 1996-Sep 2000  Yi Ji Shan Hospital, Wan nan Medical College

Jul 2003-Dec 2005  Sun Yat-sen University Cancer Center

Dec 2005-Dec 2010  Attending Physician. Sun Yat-sen University Cancer Center.

Dec 2010-present  Associate Professor Medical Oncolgy, Sun Yat-sen University Cancer Center.

1991-1996   Wan Nan Medical College, WuHu City, AnHuiProvince, P. R. China. Bachelor of Medicine (equivalent to US MD)

2000-2003   Yat-sen University, Guangzhou, P. R. China.Master of Medicine in Oncology

2005-2009   Yat-sen University, Guangzhou, P. R. China. Doctordegree of Medicine in Oncology

1. Zhang DS, Wang DS,Wang ZQ, Wang FH, Luo HY, Qiu MZ, Wang F, Li YH, Xu RH. Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabineadministered to Chinese patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2013Apr;71(4):1065-72. doi: 10.1007/s00280-013-2102-4. Epub 2013 Mar 13.

2. Li S, Zhang DS (co-first author), Sun J, Li Z, Deng L, Zou B, Zhan J, Jiang W Pharmacokinetics and tolerability of human mouse chimeric anti-CD22 monoclonalantibody in Chinese patients with CD22-positive non-Hodgkin lymphoma.MAbs. 2012 Mar 1;4(2). [Epub ahead of print]

3. Qiu MZ, Zhang DS (co-firstauthor), Ruan DY, Luo HY, Wang ZQ, Zhou ZW, Wang FH, Li YH, Xu RH. A relationship between ABO blood groups and clinicopathologiccharacteristics of patients with gastric adenocarcinoma in China.Med Oncol. 2011 Dec;28 Suppl 1:S268-73.doi: 10.1007/s12032-010-9735-5. Epub 2010 Nov 4.

4. Liu TZ, Zhang DS, LiangY, Zhou NN, Gao HF, Liu KJ, Wu HY Treatment strategiesand prognostic factors of patients with primary germ cell tumors in themediastinum. JCancer Res Clin Oncol. 2011 Nov;137(11):1607-12. doi:10.1007/s00432-011-1028-7. Epub 2011 Aug 18.

5. Wang DS, ZhangDS, Qiu MZ, Wang ZQ, Luo HY, Wang FH, Li YH, Xu RH. Prognostic factors and survival in patients with neuroendocrine tumors ofthe pancreas. Tumour Biol. 2011 Aug;32(4):697-705. doi: 10.1007/s13277-011-0170-9. Epub 2011Apr 9.

6. Qiu MZ, Wang ZQ, ZhangDS, Luo HY, Zhou ZW, Wang FH, Li YH, Jiang WQ, Xu RH. Clinicopathological characteristics and prognostic analysis of gastriccancer in the young adult in China. Tumour Biol. 2011 Jun;32(3):509-14. doi:10.1007/s13277-010-0145-2. Epub 2010 Dec 23.

7. Qiu MZ, Wang ZQ, ZhangDS, Liu Q, Luo HY, Zhou ZW, Li YH, Jiang WQ, Xu RH. Comparison of 6th and 7th AJCC TNM staging classification for carcinomaof the stomach in China. Ann Surg Oncol. 2011 Jul;18(7):1869-76. doi:10.1245/s10434-010-1542-x. Epub 2011 Jan 19.

8. Qiu MZ, Cai MY, ZhangDS, Wang ZQ, Wang DS, Li YH, Xu RH. Clinicopathologicalcharacteristics and prognostic analysis of Lauren classification in gastricadenocarcinoma in China.J Transl Med. 2013 Mar 6;11:58. doi: 10.1186/1479-5876-11-58.

9. Wang F, Xu RH, Luo HY, Zhang DS, Jiang WQ, Huang HQ, Sun XF, Xia ZJ, Guan ZZ. Clinical and prognostic analysis of hepatitis B virus infection indiffuse large B-cell lymphoma. BMC Cancer. 2008 Apr 23;8:115. doi:10.1186/1471-2407-8-115.

10. ZHANG Dong-sheng; JIANG Wen-qi;LI Su; et al. Expression of Glycoprotein 90K in Non-Hodgkin sLymphoma and Its Clinical  Significance .Chinese Journal of Cancer 2005;08.

11. ZHANGDong-sheng; JIANG Wen-qi; LI Su; et al. Detection of serun 90K/Mac-2BP in non-Hodgkin slymphoma and its clinical significance.Chian Oconlogy,2006；6.

1995-2000:Medical College, Sun Yat-Sen University. Awarded a Bachelor degree of Medicine.      

2003-2007: Sun Yat-Sen University.Awarded a Master degree of Clinical Oncology.                          

2007-2011: Sun Yat-SenUniversity. Awarded a PhD degree of Oncology.                                  

2008-2010: Karolinska Institutet,Sweden. Collaborative training for PhD student.

1. de Miranda NF, Peng R, Georgiou K, Wu C,Falk Sörqvist E, Berglund M, Chen L, Gao Z, Lagerstedt K, Lisboa S, Roos F, vanWezel T, Teixeira MR, Rosenquist R, Sundström C, Enblad G, Nilsson M, Zeng Y,Kipling D, Pan-Hammarström Q. 2013. DNA repair genes are selectively mutated indiffuse large B cell lymphomas. J Exp Med 210: 1729-42. [co-first author].                                           

2. DuL, Peng RJ, Bjorkman A, Filipe de Miranda N, Rosner C, Kotnis A, Berglund M,Liu C, Rosenquist R, Enblad G, Sundstrom C, Hojjat-Farsangi M, Rabbani H,Teixeira MR, Revy P, Durandy A, Zeng Y, Gennery AR, de Villartay JP,Pan-Hammarstrom Q. 2012. Cernunnos influences human immunoglobulin class switchrecombination and may be associated with B cell lymphomagenesis. J Exp Med 209:291-305. [co-first author].                                

3. Peng RJ, Huang ZF, Zhang YL, Yuan ZY, XiaY, Jiang WQ, Zeng YX, Li J. 2011. Circulating and tumor-infiltrating Foxp3(+)regulatory T cell subset in Chinese patients with extranodal NK/T celllymphoma. Int J Biol Sci 7: 1027-36.                                                                   

4. Peng RJ, Wang S, Shi Y, LiuD, Teng X, Qin T, Zeng Y, Yuan Z. 2011. Patients 35 years old or younger withoperable breast cancer are more at risk for relapse and survival: aretrospective matched case-control study. Breast 20: 568-73.                                                                   

5. Xia Q, Cai Y, Peng RJ, Wu G, Shi Y, JiangW. 2014. The CDK1 inhibitor RO3306 improves the response of BRCA-proficientbreast cancer cells to PARP inhibition. Int J Onco 44:735-44.                                     

6. Tan DE, Foo JN, Bei JX, Chang J, Peng RJ, Zheng X, Wei L, HuangY, Lim WY, Li J, Cui Q, Chew SH, Ebstein RP, Kuperan P, Lim ST, Tao M, Tan SH,Wong A, Wong GC, Tan SY, Ng SB, Zeng YX, Khor CC, Lin D, Seow AL, Jia WH, LiuJ. 2013. Genome-wide association study of B cell non-Hodgkin lymphomaidentifies 3q27 as a susceptibility locus in the Chinese population. Nat Genet45:804-7.                                                                         

7. Qin T, Yuan Z, Peng RJ, Bai B, Shi Y, TengX, Liu D, Wang S. 2013. HER2-positive breast cancer patients receivingtrastuzumab treatment obtain prognosis comparable with that of HER2-negativebreast cancer patients. Onco Targets Ther 6:341-7.                                                                                             

8. Xue C, Wang X, Peng RJ, Shi Y, Qin T,Liu D, Teng X, Wang S, Zhang L, Yuan Z. 2012. Distribution, clinicopathologicfeatures and survival of breast cancer subtypes in Southern China. Cancer Sci103: 1679-83.                         

9. Shi YX, Xia Q, Peng RJ, Yuan ZY, Wang SS, An X, Cao Y, TanYT, Jin Y, Cai XY, Sun YL, Teng XY, Liu DG, Jiang WQ. 2012. Comparison ofclinicopathological characteristics and prognoses between bilateral andunilateral breast cancer. J Cancer Res Clin Oncol 138: 705-14.                                                                             

10.Shi YX, Tan YT, Yuan ZY, Wang SS, Peng RJ, AnX, Cao Y, Jin Y, Cai XY, Sun YL, Teng XY, Liu DG. 2012. Comparison of overallsurvival between the early use and delayed use of Trastuzumab therapy groups: aretrospective analysis of 128 patients with HER-2-positive advanced breastcancer. Med Oncol 29: 39-47.                                     

11. Wang X, Wang SS, Peng RJ, Qin T, Shi YX, Teng XY,Liu DG, Chen WQ, Yuan ZY. 2012. Interaction of coping styles and psychologicalstress on anxious and depressive symptoms in chinese breast cancer patients.Asian Pac J Cancer Prev 13: 1645-9.                                                                                              

12. Liu DG, Wang SS, Peng RJ, Qin T, Shi YX, TengXY, Wang X, Chen WQ, Yuan ZY. 2012. Interaction of social support andpsychological stress on anxiety and depressive symptoms in breast cancerpatients. Asian Pac J Cancer Prev 12: 2523-9.                                                                   

13. Liu D, He J, Yuan Z, Wang S, Peng RJ, Shi Y,Teng X, Qin T. 2012. EGFR expression correlates with decreased disease-freesurvival in triple-negative breast cancer: a retrospective analysis based on atissue microarray. Med Oncol 29: 401-5.                                                                                              

14. He J, Peng RJ, Yuan Z, Wang S, Peng J, Lin G,Jiang X, Qin T. 2012. Prognostic value of androgen receptor expression inoperable triple-negative breast cancer: a retrospective analysis based on atissue microarray. Med Oncol 29: 406-10.                                                             

15. Liu P, Fang X, Feng Z, Guo YM, Peng RJ, LiuT, Huang Z, Feng Y, Sun X, Xiong Z, Guo X, Pang SS, Wang B, Lv X, Feng FT, LiDJ, Chen LZ, Feng QS, Huang WL, Zeng MS, Bei JX, Zhang Y, Zeng YX. 2011. Directsequencing and characterization of a clinical isolate of Epstein-Barr virusfrom nasopharyngeal carcinoma tissue by using next-generation sequencingtechnology. J Virol 85: 11291-9.                                                                         

16. Gu AD, Mo HY, Xie YB, Peng RJ, Bei JX, Peng J,Li MY, Chen LZ, Feng QS, Jia WH, Zeng YX. 2008. Evaluation of a multianalyteprofiling assay and an enzyme-linked immunosorbent assay for serologicalexamination of Epstein-Barr virus-specific antibody responses in diagnosis ofnasopharyngeal carcinoma. Clin Vaccine Immunol 15: 1684-8.                                                                          

17. Peng RJ, Sun XF, Xiang XJ, Zhen ZJ, Ling JY,Tong GL, Xia Y, Xu GC, Jiang WQ. 2009. [Efficacy and survival of 92 cases ofEwing's sarcoma family of tumor initially treated with multidisciplinarytherapy]. Ai Zheng 28: 1304-9.                                                                                                 

18. Shi YX, Peng RJ, Lin SX, Wu QL, Lin TY, SunXF, Huang HQ, Xia ZJ, Li YH, Xu RH, Liu DG, Guan ZZ, Jiang WQ. 2007. [A survivalof 103 cases of T-cell non-Hodgkin lymphoma]. Zhonghua Nei Ke Za Zhi 46:1000-2.                                                                                

19. Shi YX, Han WJ, Peng RJ., etal. Screening of RNA Intervening Targets of foxp3 Gene with FLAG Fusion Peptideand Lentivirus Vector. Journal of Sun Yat-Sen University (Medical Sciences).2007,28(6):641-644.                        

20. Peng RJ, Q.M. Dong, Y.X. Shi, Y. Cao,Z.M. Zhou, Z.Y. Yuan, S. Li, H. Liao, W.Q. Jiang. 2006. Correlative analysisbetween serum dihydropyrimidine dehydrogenase, activity, concentration of5-fluorouracil and adverse events in the treatment of advanced gastric cancerpatients. Ai Zheng 25:1039-1043.                                                    

21. Liu, D.G., R.J. Peng, F.Y. Feng, X.H.Hu, G.D. Tang, J.P. Xiong, H.Y. Zhao, Y. Guo, and Z.Z. Guan. 2006. Randomizedcontrolled trial of two kinds of home-produced docetaxel in China for advancedbreast cancer. Ai Zheng 25:1557-1560.                                                                 

22. Li, Z.G., Y.X. Shi, R.J. Peng, M.Q. Zhu, andY.Y. Wan. 2006. Blocking enhancive effect of vascular endothelial growth factoron proliferation of rhabdomyosarcoma cell line RH4 by avastin. Ai Zheng25:718-722.                                                                             

23. Cao Y, Li HL, R.J. Peng, et al. Design stageI clinical trial of target, non-cytotoxic agents. Journal of Sun Yat-SenUniversity (Medical Sciences). 2006,28(4s): 44-46.

Individualized treatment and development of novel drugs for thoracic cancer (including lung cancer, thymic carcinoma and malignant pleural mesothelioma), peri-operation treatment of NSCLC, and brain metastasis of lung cancer.

1. Modification of Pathologic T Classification for Non-small Cell Lung Cancer With Visceral Pleural Invasion: Data From 1,055 Cases of Cancers ≤ 3 cm. Liang RB, Li P, Li BT, Jin JT, Rusch VW, Jones DR, Wu YL, Liu Q, Yang J, Yang MZ, Li S, Long H, Fu JH, Zhang LJ, Lin P, Rong TH, Hou X (co-corresponding author), Lin SX, Yang HX. Chest 2021

2. Is major pathologic response sufficient to predict survival in resectable nonsmall-cell lung cancer patients receiving neoadjuvant chemotherapy? Cai JS, Li S, Yan SM, Yang J, Yang MZ, Xie CL, Li JB, Feng YF, Yang HX, Hou X. Thorac Cancer 2021 

3. SRBD1-ALK, a Novel ALK Fusion Gene Identified in an Adenocarcinoma Patient by Next-Generation Sequencing. Hou X, Xu H, Chen L. J Thorac Oncol 2019 

4. p300 promotes proliferation, migration,and  invasion via inducing epithelial-mesenchymal transition in non-small cell lung cancer cells. Hou X, Gong R, Zhan J, Zhou T, Ma Y, Zhao Y, Zhang Y, Chen G, Zhang Z, Ma S, Chen X, Gao F, Hong S, Luo F, Fang W, Yang Y, Huang Y, Chen L, Yang H, Zhang L. BMC Cancer 2018 

5. Cyclin D1 expression predicts postoperative distant metastasis and survival in resectable esophageal squamous cell carcinoma. Hou X, Liang RB, Wei JC, Xu Y, Fu JH, Luo RZ, He JH, Zhang LJ, Lin P, Yang HX. Oncotarget 2016

6. Osteopontin is a useful predictor of bone metastasis and survival in patients with locally advanced nasopharyngeal carcinoma. Hou X, Wu X, Huang P, Zhan J, Zhou T, Ma Y, Qin T, Luo R, Feng Y, Xu Y, Chen L, Zhang L. Int J Cancer 2015

7. Vascular Endothelial Growth Factor is a Useful Predictor of Postoperative Distant Metastasis and Survival Prognosis in Esophageal Squamous Cell Carcinoma. Hou X, Wei JC, Fu JH, Wang X, Luo RZ, He JH, Zhang LJ, Lin P, Yang HX. Ann Surg Oncol 2015

8. The Impact of Tumor Cell Differentiation on Survival of Patients with Resectable Esophageal Squamous Cell Carcinomas. Hou X, Gu YK, Liu XW, Fu JH, Wang X, Zhang LJ, Luo RZ, Lin P, Yang HX . Ann Surg Oncol 2015

9. Proposed Modification of the Seventh American Joint Committee on Cancer Staging System for Esophageal Squamous Cell Carcinoma in Chinese Patients. Hou X, Wei JC, Fu JH, Wang X, Zhang LJ, Lin P, Yang HX Ann Surg Oncol 2014

10. The positive lymph node ratio predicts long-term survival in patients with operable thoracic esophageal squamous cell carcinoma in China. Hou X, Wei JC, Xu Y, Luo RZ, Fu JH, Zhang LJ, Lin P, Yang HX. Ann Surg Oncol 2013

Updated November 2021

1. Schedule-dependent synergistic effect of targeting mTOR/Beclin 1 mediated autophagy-dependent senescence in the combination with chemotherapy for patients of NHL. National Natural Science Funds for Distinguished Young Scholar. 2014-2016. Principal Investigator

2. Mechanism of targeting mTOR mediated autophagy-dependent senescence in lymphoma. Guangdong Natural Science Foundation. 2013-2015. Principal Investigator

1.Huang JJ, Li YJ, Xia Y, Wang Y, WeiWX, Zhu YJ, Lin TY, Huang HQ, Jiang WQ, Li ZM. Prognostic significance of peripheral monocyte count in patients withextranodal natural killer/T-cell lymphoma. BMC Cancer. 2013 May 3;13:222.

2.Huang JJ, ZhuYJ, Xia Y, Zhao W, Lin TY, Jiang WQ, Huang HQ, Li ZM. A novel prognostic model for extranodal natural killer/T-cell lymphoma.Med Oncol. 2012Sep;29(3):2183-90.

3. Li ZM, Huang JJ, Xia Y, Sun J, Huang Y, Wang Y, Zhu YJ, Li YJ, Zhao W, Wei WX, Lin TY, Huang HQ, Jiang WQ. Blood lymphocyte-to-monocyte ratio identifies high-riskpatients in diffuse large B-cell lymphoma treated with R-CHOP. PLoS One. 2012;7(7):e41658.

4. Li ZM, Huang JJ, Xia Y, Zhu YJ, Zhao W, Wei WX, Jiang WQ, Lin TY, Huang HQ, Guan ZZ. High Ki-67 expression in diffuse large B-cell lymphomapatients with non-germinal center subtype indicates limited survival benefitfrom R-CHOP therapy. Eur J Haematol. 2012 Jun;88(6):510-7.

5. Huang JJ, Li ZM, Huang Y, Huang Y,Tian Y, He XX, Xiao J, Lin TY. Schedule-dependent inhibition of T-cell lymphoma cells by cotreatmentwith the mTOR inhibitor everolimus and anticancer drugs. Invest New Drugs. 2012 Feb;30(1):223-35. 

6. Huang JJ, Zhu YJ, Lin TY, Jiang WQ,Huang HQ, Li ZM. Beclin 1 expression predicts favorable clinical outcome in patients withdiffuse large B-cell lymphoma treated with R-CHOP. Hum Pathol. 2011Oct;42(10):1459-66.

7. Zhu YJ, Huang JJ, Xia Y, Zhao W, Jiang WQ, Lin TY, Huang HQ, Li ZM. Primary mediastinal large B-cell lymphoma (PMLBCL) inChinese patients: clinical characteristics and prognostic factors.Int J Hematol. 2011 Aug;94(2):178-84.

8. Huang JJ, Jiang WQ, Lin TY, Huang Y,Xu RH, Huang HQ, Li ZM. Absolute lymphocyte count is a novel prognostic indicator in extranodalnatural killer/T-cell lymphoma, nasal type. Ann Oncol. 2011 Jan;22(1):149-55.

9. Huang JJ, Li HR, Huang Y, Jiang WQ, XuRH, Huang HQ, Lv Y, Xia ZJ, Zhu XF, Lin TY, Li ZM.Beclin 1 expression: a predictor of prognosis in patients with extranodalnatural killer T-cell lymphoma, nasal type. Autophagy. 2010 Aug;6(6):777-83.

10. Huang JJ, Cai MY, Ye S, Li ZM, HuangHQ, Lin TY. Clinical analysis of 19 cases of subcutaneous panniculitis T-celllymphoma with literature review. Ai Zheng. 2009 Oct;28(10):1093-9.

11. Huang JJ, Lin TY. mTOR signal pathway and itsinhibitors in antitumor therapy: a review. Ai Zheng. 2007 Dec;26(12):1397-403. 

1995/09~2000/07 Sun Yat-sen University of Medical Science, Bachelor of medicine 

2003/09~2009/06 Department of Medical Oncology, Cancer center of Sun Yat-sen University, Doctor of oncology

1. Serum C-reactive protein (CRP) as a simple and independent prognostic factor in extranodal natural killer/T-cell lymphoma, nasal type. PLoS One. 2013 May 28;8(5):e64158.Li YJ, Li ZM, Xia Y,et al.

2. Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma.BMC Cancer. 2013 May 3;13:222.Huang JJ, Li YJ, Xia Y, et al.

3. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.Eur J Haematol. 2012 Jun;88(6):510-517.Li ZM, Huang JJ, Xia Y,et al.

4. Clinical characteristics of the patients with Hodgkin's lymphoma involving extranodal sites.PLoS One. 2012;7(7):e41658.Li ZM, Huang JJ, Xia Y, et al.

5. Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP.Chin J Cancer. 2012 Jul;31(7):342-7.Li ZM, Zhu YJ, Xia Y,et al.

2000 MD SUN-yat sen university of medical science, China 

2011 PhD (oncology) Sun Yat-sen University Cancer Center, China

1. Xu F, Li S, Li XL, Guo Y, Zou BY, Xu R,Liao H, Zhao HY, Zhang Y, Guan ZZ, Zhang L. Phase I and biodistribution studyof recombinant adenovirus vector-mediated herpes simplex virus thymidine kinasegene and ganciclovir administration in patients with head and neck cancer andother malignant tumors. Cancer Gene Ther. 2009 Sep;16(9):723-30.

2. Xie M, Zhang L, He CS, Xu F, Liu JL, Hu ZH,Zhao LP, Tian Y. Activation of Notch-1 enhances epithelial-mesenchymaltransition in gefitinib-acquired resistant lung cancer cells. J Cell Biochem.2011 Dec 15. [Epub ahead of print]

3. XuF, Tian Y, Huang Y, Zhang LL, Guo ZZ, Huang JJ, Lin TY. EGFR inhibitorssensitize non-small cell lung cancer cells to TRAIL-induced apoptosis. Chin JCancer. 2011 Oct;30(10):701-11.

4. ZhaoYY, Xue C, Hou X, Liao H, Li S, Zhao HY, Huang Y, Chen LK, Xu F, Liu JL, ZhangL. Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acidversus chemotherapy alone for nasopharyngeal cancer patients with bonemetastases. Eur J Cancer. 2011 Apr;47(6):848-53.

5. Zhang Y, Pan Z, Zhang X, Xu F, Zhang L. [K-RAS gene mutations inpatients with non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi. 2010Jun;13(6):602-6. Chinese. 6.       Pu XX,Deng YH, Xu F, Xiao J, Guo HQ, Huang H, Tian Y, He YJ, Lin TY.[Effect of KRASmutation on efficacy of Cetuximab combined with chemotherapy in advancedcolorectal cancer patients]. Zhonghua Wei Chang Wai Ke Za Zhi. 2009Nov;12(6):594-7. Chinese.

7. Huang H, Zhang Y, Zhao HY, Wang ZQ, Xu F,Xu GC, Zhang L, Guan ZZ. [Analysis of the efficacy and safety of gefitinib inthe treatment of recurrent advanced non-small cell lung cancer in an expandedaccess program (EAP)]. Zhonghua Zhong Liu Za Zhi. 2009 Feb;31(2):148-51.Chinese.

8. Qiu MZ, Xu F, Wang SS, Luo HY,Wang F, Li FH, Sun XF, Xu GC, Lin TY, Huang HQ, Jiang WQ, Guan ZZ, Xu RH.[Responses of 109 adult soft tissue sarcoma patients to chemotherapy]. AiZheng. 2007 Dec;26(12):1344-9. Chinese.

9. ZhangL, Zhang Y, Huang PY, Xu F, Peng PJ, Guan ZZ. Phase II clinical study ofgemcitabine in the treatment of patients with advanced nasopharyngeal carcinomaafter the failure of platinum-based chemotherapy. Cancer Chemother Pharmacol.2008 Jan;61(1):33-8.

10. Zhang Y, ZhangL, Xu F, Wang ZQ, Zhao HY, Guan ZZ, Xu GC, Pan ZK.  [Efficacy of gefitinib on advanced non-smallcell lung cancer in expanded access program (EAP)]. Ai Zheng. 2006Dec;25(12):1561-4. Chinese.

11. Xu F,Zhang L, Xiang XJ, Wang ZQ, Zhou ZM, Wang SY. [High-dose induction therapyfollowed by maintenance with recombinant human erythropoietin for 30 patientswith tumor-related anemia]. Ai Zheng. 2006 Sep;25(9):1120-2. Chinese.

12. Xiang XJ, He YJ, Li YH, Huang H, Xu F.[Clinical significance of survivin expression in peripheral T-cell lymphoma].Ai Zheng. 2006 Jun;25(6):758-61. Chinese.

13. LiN, Wang B, Zhang X, Pan Z, Xu F, Wang Z, Zhang Y, Zhang L. [Tissue microarrayanalysis of HER2 protein expression in patients with non-small cell lungcancer.] Zhongguo Fei Ai Za Zhi. 2006 Feb 20;9(1):50-54. Chinese.

Undergraduate

9/01-6/06 Bachelor degree, Medical Science, Sun Yat-sen University

Doctoral/graduate

6/06-7/08 Master degree, Medical Oncology, Sun Yat-sen University

9/12-present PhD, Oncology, Sun Yat-sen University

Professional Experience (in chronological order, earliest first)

8/08-12/11 Resident doctor, Department of medical oncology, Sun Yat-senUniversity

1. Qiu MZ, Lin JZ, Wang ZQ,Wang FH, Pan ZZ, Luo HY, Li YH, Zhou ZW, He YJ, Xu RH. Cut off value of

carcinoembryonic antigen and carbohydrate antigen 19-9 elevation levelsfor monitoring recurrence in

patients with resectable gastric adenocarcinoma. Int J Biol Markers. 2009Oct-Dec;24(4):258-64

2. Qiu MZ, Yuan ZY, Luo HY,Ruan DY, Wang ZQ, Wang FH, Li YH, Xu RH. Impact of pretreatment

hematologic profile on survival of colorectal cancer patients. TumourBiol. 2010 Aug;31(4):255-60

3. Qiu MZ, Xu RH, Ruan DY, Li ZH, Luo HY, Teng KY, Wang ZQ, Li YH,Jiang WQ. Incidence of anemia,

leukocytosis, and thrombocytosis in patients with solid tumors in China.Tumour Biol.2010 Dec;31(6):633-

41.

4. Qiu MZ, Han B, Luo HY, Zhou ZW, Wang ZQ, Wang FH, Li YH, Xu RH.Expressions of hypoxia-inducible

factor-1α and hexokinase-II in gastric adenocarcinoma: the impact onprognosis and correlation to

clinicopathologic features. Tumour Biol. 2011 Feb;32(1):159-66.

5. Qiu MZ, Li ZH, Zhou ZW, Li YH, Wang ZQ, Wang FH, Huang P, AzizF, Wang DY, Xu RH. Detection of

Carcinoembryonic Antigen Messenger RNA in Blood using QuantitativeReal-Time Reverse Transcriptase-

Polymerase Chain Reaction to Predict Recurrence of Gastric Adenocarcinoma.J Transl Med. 2010 Oct

31;8:107.

6. Teng KY, Qiu MZ (co-first author),Li ZH, Luo HY, Zeng ZL, Luo RZ, Zhang HZ, Wang ZQ, Li YH, Xu

RH. DNA polymeraseeta protein expression predicts treatment response andsurvival of metastatic gastric

adenocarcinoma patients treated with oxaliplatin-based chemotherapy. JTransl Med. 2010 Nov 27;8(1):126

7. Qiu MZ, Wang ZQ, Luo HY, Zhang DS, Zhou ZW, Li YH, Jiang WQ, XuRH. Prognostic analysis in nodenegative

gastric cancer patients in China. Tumour Biol. 2011 Jun;32(3):489-92.

8. Qiu MZ, Wang ZQ, Luo HY, Zhang DS, Zhou ZW, Li YH, Jiang WQ, XuRH. Clinicopathological

characteristics and prognostic analysis of gastric cancer in the youngadult in China. Tumour Biol. 2011

Jun;32(3):509-14.

9. Qiu MZ, Wang ZQ, Zhang DS, Liu Q, Luo HY, Zhou ZW, Li YH, JiangWQ, Xu RH. Comparison of 6th

and 7th AJCC TNM staging classification for carcinoma of the stomach inChina. Ann Surg Oncol. 2011

Jul;18(7):1869-76. Epub 2011 Jan 19.

10. Qiu MZ, Zhang DS, Ruan DY, Luo HY, Wang ZQ, Zhou ZW, Wang FH,Li YH, Xu RH. A relationship

between ABO blood groups and clinicopathologic characteristics of patientswith gastric adenocarcinoma in

China. Med Oncol. 2011 Dec;28 Suppl 1:S268-73.

11. Li ZH, Qiu MZ (co-first author), Zeng ZL, Luo HY, Wu WJ, Wang F, WangZQ, Zhang DS, Li YH, Xu RH.

Copper-transporting P-type adenosine triphosphatase (ATP7A) is associatedwith platinum-resistance in nonsmall

cell lung cancer (NSCLC). J Transl Med. 2012 Feb 3;10(1):21.

12. Qiu MZ, Qiu HJ, Wang ZQ, Ren C, Wang DS, Zhang DS, Luo HY, LiYH, Xu RH. The tumor-log odds of

positive lymph nodes-metastasis staging system, a promising new stagingsystem for gastric cancer after d2

resection in china. PLoS One. 2012;7(2):e31736. Epub 2012 Feb 14.

13. Yin Jin, Qiu MZ(co-first author),Wang DS, Zhang DS, Ren C, Bai L, Luo HY, Wang ZQ, Wang FH, Li YH,

Xu RH. Adjuvant chemotherapy for elderly patients with gastric cancerafter d2 gastrectomy. PLoS One.

2013;8(1):e53149.

14. Qiu MZ, Cai MY, Zhang DS, et al. Clinicopathological characteristics and prognosticanalysis of Lauren

classification in gastric adenocarcinoma in China. J Transl Med 2013;11:58.

15. Wei XL, Qiu MZ (co-first author),Chen WW, et al. The status of HBV infection influences metastatic

pattern and survival in Chinese patients with pancreatic cancer. J TranslMed. 2013 Oct 8;11(1):249.

16. Qiu MZ, Li Q, Wang ZQ, et al. HER2-positive patients receivingtrastuzumab treatment have a comparable

prognosis with HER2-negative advanced gastric cancer patients: Aprospective cohort observation. Int J

Cancer. 2013 Oct 23. doi:10.1002/ijc28559.

17. Qiu MZ, Wei XL, Zhang DS,et al. Efficacy and safety of capecitabine as maintenancetreatment after firstline

chemotherapy using oxaliplatin and capecitabine in advanced gastricadenocarcinoma patients: a

prospective observation. Tumour Biol. 2014 Feb 11

18. Wei XL, Qiu MZ, Lin HX, et al. Patients with old age or proximal tumors benefit from metabolic syndrome

Dr. Yaxiong Zhang is currently an attending doctor in the Department of Medical Oncology at Sun Yat-Sen University (SYSU) Cancer Center, Guangzhou, China. He mainly focuses on basic and clinical research of lung cancer. He has published more than 50 SCI-indexed papers in JNCI, Journal of Thoracic Oncology, Molecular cancer, Journal for ImmunoTherapy of Cancer, The Oncologist, Clinical Lung Cancer and other specialty periodical. Besides, he has won IASLC APLCC-Travel Grant Award and given poster presentation in ASCO, ESMO ESMO Asia and APLCC for many times.

1. Zhang Y, Chang L, Yang Y, Fang W, Guan Y, Wu A, Hong S, Zhou H, Chen G, Chen X et al: Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing. Molecular cancer 2019, 18(1):7.

2. Zhang Y, Chang L, Yang Y, Fang W, Guan Y, Wu A, Hong S, Zhou H, Chen G, Chen X et al: The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer. Journal for immunotherapy of cancer 2019, 7(1):98.

3. Zhang Y, Chang L, Fang W, Yang Y, Zhang L, Hong S, Zhou H, Guan Y, Yi X, Zhang L: Preferable background filtering for next-generation sequencing analysis in non-small cell lung cancer: pericarcinomatous tissues or peripheral blood lymphocytes? Cancer Communications (London, England) 2019, 39(1):33.

4. Zhang Z, Zhang Y, Chen G, Hong S, Yang Y, Fang W, Luo F, Chen X, Ma Y, Zhao Y et al: Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis. The oncologist 2018, 23(5):603-616.

5. Zhang Y, Zhou H, Zhang L: Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1? Journal for immunotherapy of cancer 2018, 6(1):135.

6. Zhang Y, Zhang Z, Huang X, Kang S, Chen G, Wu M, Miao S, Huang Y, Zhao H, Zhang L: Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials. Clinical lung cancer 2017, 18(5):e333-e340.

7. Zhang Y, Yang Y, Zhang Z, Fang W, Kang S, Luo Y, Sheng J, Zhan J, Hong S, Huang Y et al: Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis. Journal of the National Cancer Institute 2017, 109(2).